OncogenesisPub Date : 2026-11-09DOI: 10.1038/s41389-026-00672-8
Q Chen, D Yang, H Zong, L Zhu, L Wang, X Wang, X Zhu, X Song, J Wang
{"title":"Retraction Note: Growth-induced stress enhances epithelial-mesenchymal transition induced by IL-6 in clear cell renal cell carcinoma via the Akt/GSK-3β/β-catenin signaling pathway.","authors":"Q Chen, D Yang, H Zong, L Zhu, L Wang, X Wang, X Zhu, X Song, J Wang","doi":"10.1038/s41389-026-00672-8","DOIUrl":"10.1038/s41389-026-00672-8","url":null,"abstract":"","PeriodicalId":19489,"journal":{"name":"Oncogenesis","volume":"15 1","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13748570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenesisPub Date : 2026-10-24DOI: 10.1038/s41389-026-00667-5
Siva Chander Chabattula, Patrick T Ball, Alok Kartha, Kiran Kumar Reddi, Yvonne J K Edwards, Romi Gupta
{"title":"Co-targeting ASAH1 and the histone reader BRD1 potently suppresses TNBC growth through the transcriptional repressor BCL6.","authors":"Siva Chander Chabattula, Patrick T Ball, Alok Kartha, Kiran Kumar Reddi, Yvonne J K Edwards, Romi Gupta","doi":"10.1038/s41389-026-00667-5","DOIUrl":"10.1038/s41389-026-00667-5","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with limited targeted therapeutic options, leading to higher mortality rates compared to other breast cancer subtypes. In our previous study, we identified that N-acyl sphingosine amidohydrolase 1 (ASAH1) is overexpressed in TNBC cells, and its genetic and pharmacological targeting suppresses TNBC growth and progression. In the current study, we performed a small-molecule screen using epigenetic inhibitors in combination with the ASAH1 inhibitor carmofur to identify potential epigenetic regulators that can be co-targeted to enhance the antitumor effect of carmofur. We identified the bromodomain containing protein 1 (BRD1) inhibitors (BAY-299, NI57 and OF1), which when combined with carmofur led to stronger inhibition of TNBC tumor growth in cell culture and in in vivo model compared to either single agent alone. Mechanistically, BAY-299 in combination with carmofur induced higher expression of the transcriptional repressor B-cell lymphoma 6 (BCL6), resulting in stronger inhibition of the anti-apoptotic gene, B-cell lymphoma 2 (BCL2) than either treatment alone. This consequently led to enhanced apoptosis in TNBC cells treated with both BAY-299 and carmofur. Collectively, these results identify a previously undocumented therapeutic combination of BRD1 inhibitors and ASAH1 inhibitor carmofur as a promising treatment strategy for TNBC.</p>","PeriodicalId":19489,"journal":{"name":"Oncogenesis","volume":"15 1","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13713984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149287989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenesisPub Date : 2026-10-22DOI: 10.1038/s41389-026-00658-6
Ana Carolina B Sant'Anna-Silva, Chloe Del Bove, Georgios Efthymiou, Emma Henry, Laura Henry, Jigna Kundnani, Rodrigue Rossignol, Sophie Zimmermann
{"title":"Meeting Report of the 6th edition of metabolism and cancer symposium.","authors":"Ana Carolina B Sant'Anna-Silva, Chloe Del Bove, Georgios Efthymiou, Emma Henry, Laura Henry, Jigna Kundnani, Rodrigue Rossignol, Sophie Zimmermann","doi":"10.1038/s41389-026-00658-6","DOIUrl":"10.1038/s41389-026-00658-6","url":null,"abstract":"<p><p>The 6th International Meeting \"Metabolism and Cancer\" was held at the Convention Center in La Grande Motte, France, on October 8-10, 2025. The three-day conference brought together 240 participants from eleven countries and featured 29 scientific presentations, including 15 invited lectures delivered by leading investigators in the field of oncometabolism. The program was structured into four thematic sessions: (i) diet, cachexia, microbiome, and microenvironment; (ii) stem cells and metabolic plasticity; (iii) epigenetics, epitranscriptomics, and metabolism; and (iv) metabolic control of drug resistance, therapy, and biomarkers. This meeting report highlights key conceptual advances and emerging directions discussed during the conference. Future progress in cancer metabolism will depend on elucidating the cross-talk between tumors and peripheral tissues, as organism-level metabolic regulation is likely to critically influence tumor growth, plasticity, and treatment sensitivity. Moving forward, a systems-level integration of metabolic, genomic, and spatial data is poised to redefine cancer metabolism from a descriptive field into a source of actionable vulnerabilities for precision oncology.</p>","PeriodicalId":19489,"journal":{"name":"Oncogenesis","volume":"15 1","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149245828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenesisPub Date : 2026-10-19DOI: 10.1038/s41389-026-00670-w
Xiaoye Jin, Xiayuan Lou, Haoxiang Qi, Chao Zheng, Bo Li, Xuerong Siwu, Ren Liu, Qiaoli Lv, An Zhao, Jian Ruan, Ming Jiang
{"title":"Correction: NRF2 signaling plays an essential role in cancer progression through the NRF2-GPX2-NOTCH3 axis in head and neck squamous cell carcinoma.","authors":"Xiaoye Jin, Xiayuan Lou, Haoxiang Qi, Chao Zheng, Bo Li, Xuerong Siwu, Ren Liu, Qiaoli Lv, An Zhao, Jian Ruan, Ming Jiang","doi":"10.1038/s41389-026-00670-w","DOIUrl":"10.1038/s41389-026-00670-w","url":null,"abstract":"","PeriodicalId":19489,"journal":{"name":"Oncogenesis","volume":"15 1","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13680612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Stanniocalcin 1 contributes to glioma stem cells phenotypic plasticity through NOTCH1/STAT3/GFPT2 axis.","authors":"Feng Tian, Kangming Zhu, Yanfei Sun, Shuhua Guo, Xing Guo, Chuanxin Wang, Shuo Xu","doi":"10.1038/s41389-026-00653-x","DOIUrl":"10.1038/s41389-026-00653-x","url":null,"abstract":"<p><p>Glioma stem cells (GSCs) are key drivers of glioblastoma (GBM) tumorigenesis, invasion, therapy resistance, and recurrence and exhibit remarkable phenotypic plasticity. Stanniocalcin 1 (STC1) has been implicated in tumor progression and cancer stemness; however, its role and the molecular mechanisms through which it shapes GSC plasticity and malignant traits remain poorly understood. Here, transcriptomic RNA sequencing identified STC1 as a malignancy-associated gene enriched in GBM and mesenchymal (MES)-like GSCs. Comprehensive bioinformatic analyses further validated that STC1 was highly expressed in MES-like GBM/GSCs and closely associated with poor patient survival. Functional studies revealed that STC1 promoted multiple malignant properties of GSCs, including self-renewal, migration, invasion, tumorigenicity, and cellular plasticity. Conversely, STC1 silencing attenuated these effects. Mechanistically, STC1 activated the NOTCH1/STAT3 signaling cascade, leading to transcriptional upregulation of GFPT2, a key rate-limiting enzyme of the hexosamine biosynthetic pathway. This subsequently enhanced global O-GlcNAcylation, including modification of P65, thereby facilitating GSC plasticity and malignant progression. Genetic and pharmacological interventions targeting this signaling axis effectively mitigated the oncogenic effects driven by STC1. In conclusion, our study reveals that STC1 is a key regulator of GSC phenotypic plasticity and aggressiveness through the NOTCH1/STAT3/GFPT2/O-GlcNAcylation pathway. These results provide new mechanistic insights into GBM progression and suggest that targeting STC1-associated signaling networks may represent a potential therapeutic strategy for GBM.</p>","PeriodicalId":19489,"journal":{"name":"Oncogenesis","volume":"15 1","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13661601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149183363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Disruption of the AR/ZNF217/PROM2 axis sensitizes prostate cancer to ferroptosis and enzalutamide therapy.","authors":"Wenjun Hao, Peng Liang, Wanglong Zheng, Minglu Sheng, Yulin Peng, Xiang Gao, Haolin Zhao, Yuyan Zhu, Yanlong Wang, Bo Fan, Zhihong Dai, Xu Sun, Liang Wang, Huan Qi, Ying Wang, Yan Wang, Zhenlong Yu, Zhiyu Liu","doi":"10.1038/s41389-026-00649-7","DOIUrl":"10.1038/s41389-026-00649-7","url":null,"abstract":"<p><p>Dysregulation of androgen receptor (AR) signaling is a key molecular driver of prostate cancer development and its transition to castration-resistant disease. Although emerging evidence indicates that AR may influence ferroptosis by modulating lipid peroxidation and antioxidant systems, the complete transcriptional network through which AR regulates ferroptosis remains incompletely defined. In this study, we identify the transcription factor ZNF217 as a direct downstream target of AR, which is aberrantly upregulated in prostate cancer and associated with poor clinical outcomes. ZNF217 enhances the transcriptional activity of its downstream effector PROM2, thereby suppressing ferroptosis and promoting cell survival. Functional assays demonstrate that ZNF217 silencing markedly amplifies ferroptotic features, whereas ZNF217 overexpression partially alleviates ferroptosis-induced cellular damage. Building on these findings, we established a drug screening system based on ZNF217 expression and identified the compound RSL3 from a panel of 13 ferroptosis inducers, which potently suppresses ZNF217 expression. Further investigations revealed that combined treatment with RSL3 and the AR antagonist enzalutamide produced a synergistic antitumor response in cellular and animal models, accompanied by marked attenuation of AR/ZNF217/PROM2 pathway activity and reduced tumor burden. Collectively, these findings identify AR/ZNF217/PROM2 signaling as a central determinant of ferroptotic vulnerability in prostate cancer and suggest that targeting this pathway may enhance sensitivity to AR inhibition, providing a molecular rationale for combination therapy in castration-resistant prostate cancer.</p>","PeriodicalId":19489,"journal":{"name":"Oncogenesis","volume":"15 1","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13740269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149343136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"CYBRD1 is transcriptionally regulated by RUNX1 and mediates JAK2/STAT3 signaling activation during ovarian cancer progression.","authors":"Yalong Deng, Qiyu Gan, Xia Huang, Liang Zhu, Lina Liu, Guozeng Wang, Linlin Chang, Rui Shi, Sufeng Qiang, Wenzhi Duan, Qin Liu, HuiMin Lei, Jingxin Cheng","doi":"10.1038/s41389-026-00646-w","DOIUrl":"10.1038/s41389-026-00646-w","url":null,"abstract":"<p><p>Metastasis and chemoresistance are the leading causes of death in high-grade serous ovarian carcinoma (HGSOC). Our previous studies revealed that the membrane protein cytochrome b reductase 1 (CYBRD1) is a critical prognostic marker for HGSOC, but its role in HGSOC progression and molecular mechanisms remain unclear. Here, we reveal that CYBRD1 is a druggable factor that drives chemoresistance and tumor progression in HGSOC. Importantly, compared with that in their cisplatin-sensitive counterparts, CYBRD1 expression is elevated in cisplatin-resistant cells. Through genetic manipulation, we showed that CYBRD1 inhibition effectively re‑sensitizes cells to cisplatin and suppresses proliferation, migration, and invasion. Targeted gene expression profiling indicated that CYBRD1 inhibition markedly attenuated JAK2/STAT3 signaling. Using point mutants, we confirmed that phosphorylation of CYBRD1 at Tyr252 is essential for the interaction with JAK2, subsequent activation of JAK2/STAT3 signaling and mediating HGSOC progression. CYBRD1 inhibition significantly restored cisplatin sensitivity and exerted a synergistic tumoricidal effect. In vivo, combined CYBRD1 inhibition and cisplatin markedly reduced tumor metastasis. Furthermore, we found that RUNX1 regulates CYBRD1 transcription. These findings highlight that the combination of CYBRD1 inhibitors and conventional chemotherapy is a promising therapeutic strategy for HGSOC, especially in chemoresistant patients.</p>","PeriodicalId":19489,"journal":{"name":"Oncogenesis","volume":"15 1","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13645810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenesisPub Date : 2026-07-25DOI: 10.1038/s41389-026-00647-9
Paula Morales-Sánchez, Joan Montero
{"title":"BH3 profiling analyses for functional precision medicine.","authors":"Paula Morales-Sánchez, Joan Montero","doi":"10.1038/s41389-026-00647-9","DOIUrl":"10.1038/s41389-026-00647-9","url":null,"abstract":"<p><p>Evasion of apoptosis is a central hallmark of cancer and a major driver of therapeutic resistance. While genomic and transcriptomic profiling have reshaped our understanding of cancer, they often fail to predict whether a cell will die when treated. BH3 profiling and its variants solve this by directly interrogating mitochondrial apoptotic priming and its reliance on anti-apoptotic dependencies by directly exposing cells to defined BH3-only peptides. Over the past decade, researchers have successfully applied these assays across a wide range of hematologic malignancies, solid tumors, and resistant cancer models. This functional assay predicts treatment response, identifies rational drug combinations, and reveals mechanisms of both intrinsic and acquired resistance to apoptosis. In hematologic malignancies, functional dependence on BCL-2 measured by BH3 profiling strongly correlates with sensitivity to venetoclax, while reduced mitochondrial priming underlies resistance. In solid tumors, these analyses have uncovered previously unappreciated reliance on BCL-xL and MCL-1, enabling the design of effective combination strategies despite limited single-agent activity of BH3 mimetics. Recent methodological advances, including high-throughput and dynamic BH3 profiling, further highlight the changing and heterogeneous nature of apoptotic regulation within tumors. This review evaluates the preclinical and early clinical evidence for BH3 profiling in precision oncology. Beyond assessing its current performance, we examine the methodological requirements for its transition into clinical settings and its potential to address the limitations of current personalized cancer therapies.</p>","PeriodicalId":19489,"journal":{"name":"Oncogenesis","volume":"15 1","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149228259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenesisPub Date : 2026-07-24DOI: 10.1038/s41389-026-00645-x
Sang-Nee Tan
{"title":"Apoptosis-driven chromosomal rearrangements in cancer: CAD cleavage, nuclear architecture, and microhomology-mediated end joining.","authors":"Sang-Nee Tan","doi":"10.1038/s41389-026-00645-x","DOIUrl":"10.1038/s41389-026-00645-x","url":null,"abstract":"<p><p>Chromosomal rearrangements are hallmarks of many cancers, yet the mechanisms governing breakpoint selection remain incompletely understood. Emerging evidence suggests that sublethal apoptotic signaling may contribute to structural genome remodeling. Oxidative stress and inflammatory stimuli trigger caspase activation and the release of caspase-activated DNase (CAD), which preferentially cleaves DNA at matrix association regions/scaffold attachment regions (MAR/SARs) that anchor chromatin loops to the nuclear scaffold. When apoptotic execution is incomplete and cells undergo recovery, a process termed anastasis, CAD-induced double-strand breaks (DSBs) can be repaired through error-prone end-joining pathways, including classical non-homologous end joining (cNHEJ) and microhomology-mediated end joining (MMEJ), producing rearrangements enriched at MAR/SAR-associated genomic regions. Drawing on mechanistic studies in leukemia and experimental evidence in nasopharyngeal carcinoma (NPC), this review outlines a framework linking apoptotic DNA fragmentation, nuclear architecture, and error-prone repair to recurrent structural variations, and discusses how shared inflammation- and virus-associated oxidative stress may promote analogous mechanisms of breakpoint formation in other malignancies. The convergence of findings across hematologic and epithelial malignancies strengthens the biological plausibility and potential generalizability of this model across inflammation- and stress-associated cancers. This perspective suggests that at least a subset of cancer-associated chromosomal rearrangements may arise not purely as stochastic by-products of genomic instability, but as structured outcomes of dysregulated cell-death programs acting on vulnerable chromatin domains. Beyond its mechanistic implications, this framework may inform biomarker discovery through apoptosis-associated breakpoint features and highlight potential therapeutic vulnerabilities in apoptosis-surviving cells, including dependence on polymerase theta-mediated repair or regulation of apoptotic execution.</p>","PeriodicalId":19489,"journal":{"name":"Oncogenesis","volume":"15 1","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13408182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148605941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}